Efficacy and safety of daratumumab in pure red cell aplasia after allogeneic transplantation: Dutch real-world data
Blood Adv
.
2024 Apr 9;8(7):1683-1686.
doi: 10.1182/bloodadvances.2023011190.
Authors
Flores Weverling
1
,
Mieke Roeven
2
,
Clara Nijssen
1
,
Annoek E C Broers
3
,
Elisabeth Dovern
4
,
Anna van Rhenen
1
,
Geerte van Sluis
5
,
Carin L E Hazenberg
6
,
Peter van Balen
7
,
Maria T Kuipers
4
,
Karen M K de Vooght
8
,
Linde Morsink
6
,
Jürgen Kuball
1
,
Erfan Nur
4
,
Moniek A de Witte
1
Affiliations
1
Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.
2
Department of Hematology, Radboud University Medical Center; Nijmegen, The Netherlands.
3
Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
4
Department of Hematology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
5
Department of Hematology, Isala Hospital, Zwolle, The Netherlands.
6
Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands.
7
Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.
8
Central Diagnostic Laboratory, University Medical Center Utrecht, Utrecht, The Netherlands.
PMID:
38231018
PMCID:
PMC11006807
DOI:
10.1182/bloodadvances.2023011190
No abstract available
MeSH terms
Antibodies, Monoclonal / adverse effects
Humans
Red-Cell Aplasia, Pure* / drug therapy
Red-Cell Aplasia, Pure* / etiology
Transplantation, Homologous
Substances
daratumumab
Antibodies, Monoclonal